Clinical Trial Update: ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ARX788 for HER2-low breast cancer (locally advanced unresectable or metastatic) is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer
• Low Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• ARX788

Snippet

Sponsor: Laura Huppert, MD, BA | Conditions: HER2 Low Breast Carcinoma, Triple Negative Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING